MaaT Pharma SA (MAAT.PA)
MaaT Pharma SA
70 Avenue Tony Garnier
Lyon 69007
France
33 4 28 29 14 00
https://www.maatpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 52
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Herve Affagard | CEO, Co-Founder & Director | 271.2k | N/D | 1975 |
| Dr. Joel Dore Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
| Mr. Pierre Rimbaud | Co-Founder | N/D | N/D | N/D |
| Ms. Sian Crouzet | Chief Financial Officer | N/D | N/D | N/D |
| Ms. Carole Schwintner | Chief Technology Officer | N/D | N/D | N/D |
| Dr. Nathalie Corvaia Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
| Guilhaume Debroas Ph.D. | Head of Investor Relations | N/D | N/D | N/D |
| Dr. Emilie Plantamura | Head of Clinical Development | N/D | N/D | N/D |
| Mr. Jonathan Chriqui Pharm.D. | Chief Business Officer | N/D | N/D | N/D |
Descripción
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Gestión corporativa
La calificación ISS Governance QuickScore de MaaT Pharma SA a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
